Clinical trials: SAR
Allergic Rhinitis, Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
This study is an 8 day, randomised, double blind, 2-way crossover trial of repeat doses of intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612118
- Testing
- GSK256066, azelastine hydrochloride
- Where
- Austria
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SAR
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Coronavirus disease (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a major threat to human health.
- Trial name
- NCT04777981
- Testing
- CBDRA60 supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Anewsha Therapeutics Inc.
Rhinitis, Allergic, Seasonal
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)
This is an 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
- Trial name
- NCT00612820
- Testing
- GSK256066, fluticasone propionate
- Where
- Austria
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Conjunctivitis
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.
- Trial name
- NCT00818805
- Testing
- Olopatadine 0.1%, Tranilast 0.5%
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Hay Fever
Safety and Efficacy Study of rEV131 in Allergic Rhinitis
The purpose of this study is to see whether rEV131 when given as a nasal spray in a single dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay fever) caused by an allergen challenge.
- Trial name
- NCT00247520
- Testing
- topical nasal rEV131
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Evolutec Group
Seasonal Allergic Rhinitis (SAR)
A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure
This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
- Trial name
- ALDP001 (NCT07219849)
- Testing
- ALDP001 Nasal Spray
- Where
- Canada
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Alixer Nexgen Therapeutics Limited